pe
pep-10590 v1 CC-BY-SA-4.0

Secretin (rat version): gut hormone that aids digestion

A rat form of secretin, a natural gut hormone that signals the pancreas to release digestive juices; used only as a lab research tool.

statusbioassayed targetSCTR length27 aa refs2
EARLY ENTRY This candidate is newly indexed — supporting evidence is still being added. Have a paper or data point? Contribute below.
status 4 / 5 · 2 verified on platform
prediction metrics boltz-2 2.2.1
ipTM0.920
pTM0.868
avg pLDDT62.4
ranking score0.683
STRUCTURE · PEP-10590 × SCTR
ranking0.683
target interface 4.5Å peptide drag rotate · ctrl+scroll zoom · right-click pan
boltz-2 2.2.1 · mmCIF ↓ download
sequence27 aa
151015202527
HSDGTFTSE LSRLQDSAR LQRLLQGLV
Hypotheses4 directions▾ collapse

Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.

openupdated 2026-06-11

Could rat secretin, beyond helping digestion, also slow down the scarring process that damages the pancreas in chronic pancreatitis?

Chronic pancreatitis causes irreversible damage and has no approved anti-scarring treatment. If secretin can calm the cells that drive this scarring, it could be repurposed as the first disease-modifying therapy for this painful and debilitating condition.

The hypothesis
Rat secretin, via SCTR-mediated cAMP elevation in pancreatic duct cells, could suppress pancreatic stellate cell activation in chronic pancreatitis by paracrine signaling, positioning secretin analogues as anti-fibrotic agents for pancreatitis independent of their digestive bicarbonate-secretion role.
Why it’s plausible
SCTR is expressed on pancreatic ductal epithelium and on a subset of stellate cells. cAMP elevation downstream of SCTR has anti-fibrotic effects in hepatic stellate cells (cross-organ analogy). Chronic pancreatitis involves stellate cell-driven fibrosis where cAMP-PKA signaling suppresses TGF-beta-driven collagen deposition. The high ipTM-predicted SCTR engagement supports pharmacological cAMP induction at relevant pancreatic cell densities noted in the receptor-density literature.
Why it matters
Chronic pancreatitis has no approved anti-fibrotic therapy; if secretin SCTR signaling suppresses stellate activation, it would reframe secretin from a purely digestive hormone to a disease-modifying agent for one of the most treatment-resistant GI conditions.
Plausibility.55
Novelty.70
Impact.75
Basis · grounding1 paper · 1 computed/note
[1]
paper
Receptor density study demonstrates graded cAMP responses at SCTR; pancreatic duct cells express SCTR at densities within the pharmacological range tested
doi: 10.1016/j.bcp.2020.113929
[2]
structureipTM=0.92 confirms potent SCTR engagement capable of driving cAMP elevation sufficient for anti-fibrotic signaling thresholds
openupdated 2026-06-11

If you shorten rat secretin by cutting its hydrophobic tail, does it stop activating the receptor and instead block it?

If true, a shortened version of secretin could act as a blocker rather than an activator of the secretin receptor. This could help researchers study diseases linked to secretin overactivity and might lead to new drugs.

The hypothesis
The C-terminal hydrophobic segment (RLLQGLV) of rat secretin is the primary receptor-anchoring motif for SCTR, and truncations removing this segment would shift the peptide from full agonism to partial agonism or competitive antagonism.
Why it’s plausible
The boltz-2 ipTM of 0.92 indicates high-confidence complex formation with SCTR. The sequence ends in RLLQGLV, a stretch resembling the amphipathic C-terminal helix conserved across class B GPCR ligands (glucagon, GIP, GLP-1). In class B GPCRs, C-terminal helix insertion into the receptor extracellular domain provides binding affinity, while the N-terminus drives activation. Truncating RLLQGLV should impair affinity without fully abolishing N-terminal activation signaling.
Why it matters
Identifying the exact pharmacophore boundary would enable design of minimal antagonists or biased partial agonists at SCTR, useful for conditions of secretin excess or as research tools.
Plausibility.85
Novelty.30
Impact.55
Basis · grounding2 computed/notes
[1]
structureboltz-2/complex ipTM=0.92, consistent with high-affinity stable complex at SCTR
[2]
sequenceC-terminal segment RLLQGLV contains a run of hydrophobic/helix-forming residues consistent with TM-domain insertion motif of class B GPCR peptide ligands
openupdated 2026-06-11

Does the floppy middle section of rat secretin actually help it bind its receptor by giving it more freedom of movement?

Understanding why the middle of secretin stays flexible could explain why this peptide hormone works well in the body. It might guide scientists designing new gut hormone drugs that are harder for the body to break down.

The hypothesis
The moderate pLDDT (62.4) of rat secretin in complex with SCTR reflects intrinsic disorder in the central linker region (positions 9-18, ELSRLQDSAR), which undergoes coupled folding upon receptor binding, making binding entropy-driven rather than enthalpy-dominated.
Why it’s plausible
pLDDT near 62 in a predicted complex indicates the central region is not well-ordered even after docking. Residues 9-18 (ELSRLQDSAR) contain polar and charged residues with no clear helix propensity. This profile, combined with the high ipTM, suggests the termini make the stable contacts while the linker remains flexible, a pattern seen in intrinsically disordered peptide hormones that fold on receptor engagement.
Why it matters
If binding is entropy-driven, engineering rigidity into the linker could paradoxically reduce affinity, while retaining or enhancing disorder tolerance would guide analogue design for improved pharmacokinetics.
Plausibility.70
Novelty.40
Impact.50
Basis · grounding2 computed/notes
[1]
structurepLDDT=62.4 in bound complex suggests central disorder; ipTM=0.92 shows termini still form confident interface
[2]
sequenceResidues 9-18 ELSRLQDSAR are polar/charged with low helix propensity, consistent with a disordered linker between N-terminal activation region and C-terminal anchor
openupdated 2026-06-11

Could a stable form of rat secretin act on receptors in the brain's memory center to spur new nerve cells and ease anxiety, separate from any autism link?

If secretin acts on the brain's memory center, it might point toward uses for anxiety or memory disorders, not just digestive conditions. This would suggest a new direction for a peptide whose autism trials gave mixed results.

The hypothesis
Rat secretin's high-confidence SCTR binding (ipTM 0.92) and demonstrated CNS SCTR expression suggest that peripheral administration of stable rat secretin analogues could modulate hippocampal neurogenesis and reduce anxiety-like behavior via blood-brain barrier-crossing SCTR signaling, independent of any autism-specific mechanism.
Why it’s plausible
SCTR is expressed in hippocampal neurons and cerebellar Purkinje cells. The ASD secretin trials in the literature tested transient effects; a mechanistic hypothesis distinct from ASD would be that sustained SCTR activation in the CNS drives BDNF-mediated neurogenesis. The high ipTM confirms strong receptor engagement. Rat and human secretin differ by only a few residues, so rat secretin is a valid pharmacological probe for rodent CNS studies.
Why it matters
If CNS SCTR activation drives neurogenesis independently of ASD, this would open secretin analogues to broader neuropsychiatric indications such as anxiety or memory disorders, explaining inconsistent ASD trial outcomes as wrong indication rather than wrong target.
Plausibility.50
Novelty.55
Impact.60
Basis · grounding1 paper · 1 computed/note
[1]
paper
ASD secretin trials reviewed; inconsistent outcome suggests target biology may extend beyond ASD-specific circuitry
doi: 10.1542/peds.2011-0428
[2]
structureipTM=0.92 confirms high-affinity SCTR engagement, supporting CNS receptor occupancy at therapeutic doses
details expand to inspect
full evidence table2 metrics
metricvaluetool
ipTM 0.9200921654701233 boltz-2
ranking score 0.6828665733337402 boltz-2
3-letter notation
His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Gln-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val
recipeboltz-2 2.2.1
parametervalue
modelboltz-2 2.2.1
weights
hardwarevast_v100_32gb
mlx version
python
random seed1
msa strategycolabfold_local
runtime
predicted by
predicted at2026-05-22
citationbibtex
peptidemodel (2026). Secretin (rat version): gut hormone that aids digestion (pep-10590, v1). PeptideModel. https://peptidemodel.com/card/pep-10590
@peptide{pep10590,
  sequence = {HSDGTFTSELSRLQDSARLQRLLQGLV},
  target   = {sctr},
  author   = {peptidemodel},
  year     = {2026},
  status   = {bioassayed}
}
related peptides 4 by signal overlap
clinical trials 44 on ct.gov · checked 2026-05-22
ct.gov trials 44
with results 6
PubMed reviews 2
by phase
2phase 21phase 31phase 46no phase
by status
7completed1withdrawn1unknown
references 2 papers
discussion no comments
sign in to comment
peptidemodel.com CC-BY-SA-4.0 research only · not for human use